Published in Invest Ophthalmol Vis Sci on July 01, 2015
Cryopreserved Mesenchymal Stromal Cells Maintain Potency in a Retinal Ischemia/Reperfusion Injury Model: Toward an off-the-shelf Therapy. Sci Rep (2016) 0.84
An intraocular drug delivery system using targeted nanocarriers attenuates retinal ganglion cell degeneration. J Control Release (2017) 0.80
Microglial migration and interactions with dendrimer nanoparticles are altered in the presence of neuroinflammation. J Neuroinflammation (2016) 0.78
Nanotechnology Approaches to Targeting Inflammation and Excitotoxicity in a Canine Model of Hypothermic Circulatory Arrest-Induced Brain Injury. Ann Thorac Surg (2016) 0.78
Nanoscale effects in dendrimer-mediated targeting of neuroinflammation. Biomaterials (2016) 0.78
Friend or Foe? Resident Microglia vs Bone Marrow-Derived Microglia and Their Roles in the Retinal Degeneration. Mol Neurobiol (2016) 0.76
Comprehensive analysis of mouse retinal mononuclear phagocytes. Nat Protoc (2017) 0.75
Protective effects on the retina after ranibizumab treatment in an ischemia model. PLoS One (2017) 0.75
Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci Transl Med (2012) 3.43
Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res (2004) 3.08
Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release (2000) 3.07
Microglia biology in health and disease. J Neuroimmune Pharmacol (2006) 2.53
Immunology of age-related macular degeneration. Nat Rev Immunol (2013) 2.14
Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today (2010) 2.03
Retinal ischemia and reperfusion causes capillary degeneration: similarities to diabetes. Invest Ophthalmol Vis Sci (2007) 1.90
The effect of surface functionality on cellular trafficking of dendrimers. Biomaterials (2008) 1.74
Heterogeneity in localization of isoforms of TGF-beta in human retina, vitreous, and choroid. Invest Ophthalmol Vis Sci (1993) 1.61
Microglial activation in human diabetic retinopathy. Arch Ophthalmol (2008) 1.49
Age related macular degeneration and drusen: neuroinflammation in the retina. Prog Neurobiol (2011) 1.44
Diabetic eye disease. Lancet (1997) 1.28
Apoptosis and caspases after ischemia-reperfusion injury in rat retina. Invest Ophthalmol Vis Sci (1999) 1.21
The role of the immune response in age-related macular degeneration. Int J Inflam (2013) 1.16
Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. Biomaterials (2011) 1.10
Opioid receptor-activation: retina protected from ischemic injury. Invest Ophthalmol Vis Sci (2009) 1.09
Minocycline prevents retinal inflammation and vascular permeability following ischemia-reperfusion injury. J Neuroinflammation (2013) 1.08
Intrinsic targeting of inflammatory cells in the brain by polyamidoamine dendrimers upon subarachnoid administration. Nanomedicine (Lond) (2010) 1.04
Heterogeneous populations of microglia/macrophages in the retina and their activation after retinal ischemia and reperfusion injury. Exp Eye Res (2005) 1.02
Effects of ischemic preconditioning and bevacizumab on apoptosis and vascular permeability following retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci (2010) 1.02
Neuroprotective effect of minocycline in a rat model of branch retinal vein occlusion. Exp Eye Res (2013) 1.02
The role of microglia in diabetic retinopathy. J Ophthalmol (2014) 1.00
Interleukin-6 in retinal ischemia reperfusion injury in rats. Invest Ophthalmol Vis Sci (2003) 0.99
Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes. Graefes Arch Clin Exp Ophthalmol (2013) 0.98
Age-related macular degeneration: insights into inflammatory genes. J Ophthalmol (2014) 0.98
Biodistribution of fluorescently labeled PAMAM dendrimers in neonatal rabbits: effect of neuroinflammation. Mol Pharm (2013) 0.94
Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther (2005) 0.94
Anti-inflammatory and anti-oxidant activity of anionic dendrimer-N-acetyl cysteine conjugates in activated microglial cells. Int J Pharm (2009) 0.91
In vivo distribution and toxicity of PAMAM dendrimers in the central nervous system depend on their surface chemistry. Mol Pharm (2012) 0.90
Microglia in the outer retina and their relevance to pathogenesis of age-related macular degeneration. Adv Exp Med Biol (2012) 0.90
Dendrimer nanoparticles for ocular drug delivery. J Ocul Pharmacol Ther (2013) 0.89
Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. Exp Eye Res (2004) 0.87
Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium. Nanomedicine (2008) 0.87
Brain and retinal microglia in health and disease: an unrecognized target of the renin-angiotensin system. Clin Exp Pharmacol Physiol (2013) 0.83
The role of Müller glia and microglia in glaucoma. Cell Tissue Res (2013) 0.83
Nanomedicine in cerebral palsy. Int J Nanomedicine (2013) 0.80